Discovery of a Novel Class of Orally Active Trypanocidal N-Myristoyltransferase Inhibitors
Journal of Medicinal Chemistry2011Vol. 55(1), pp. 140–152
Citations Over TimeTop 10% of 2011 papers
Stephen Brand, Laura A. T. Cleghorn, Stuart P. McElroy, David A. Robinson, Victoria Smith, Irene Hallyburton, Justin R. Harrison, Neil R. Norcross, Daniel Spinks, Tracy Bayliss, Suzanne Norval, Laste Stojanovski, Leah S. Torrie, Julie A. Frearson, Ruth Brenk, Alan H. Fairlamb, Michael A. J. Ferguson, Kevin D. Read, Paul G. Wyatt, Ian H. Gilbert
Abstract
N-Myristoyltransferase (NMT) represents a promising drug target for human African trypanosomiasis (HAT), which is caused by the parasitic protozoa Trypanosoma brucei. We report the optimization of a high throughput screening hit (1) to give a lead molecule DDD85646 (63), which has potent activity against the enzyme (IC(50) = 2 nM) and T. brucei (EC(50) = 2 nM) in culture. The compound has good oral pharmacokinetics and cures rodent models of peripheral HAT infection. This compound provides an excellent tool for validation of T. brucei NMT as a drug target for HAT as well as a valuable lead for further optimization.
Related Papers
- → Novel Synthesis, Cytotoxic Evaluation, and Structure−Activity Relationship Studies of a Series of α-Alkylidene-γ-lactones and Lactams(2005)107 cited
- → Synthesis, topoisomerase I inhibition and structure–activity relationship study of 2,4,6-trisubstituted pyridine derivatives(2004)95 cited
- → Molecular docking and structure–activity relationship studies on benzothiazole based non-peptidic BACE-1 inhibitors(2010)22 cited
- → Ring-truncated deguelin derivatives as potent Hypoxia Inducible Factor-1α (HIF-1α) inhibitors(2015)28 cited
- → Synthesis and structure-activity relationships of a series of penicillin-derived HIV proteinase inhibitors containing a stereochemically unique peptide isostere(1993)24 cited